344 related articles for article (PubMed ID: 23820429)
1. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
[TBL] [Abstract][Full Text] [Related]
2. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
4. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
Picker SM; Steisel A; Gathof BS
Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
[TBL] [Abstract][Full Text] [Related]
5. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
Picker SM; Oustianskaia L; Schneider V; Gathof BS
Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
[TBL] [Abstract][Full Text] [Related]
6. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
Picker SM; Steisel A; Gathof BS
Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
[TBL] [Abstract][Full Text] [Related]
7. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
Tauszig ME; Picker SM; Gathof BS
Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
[TBL] [Abstract][Full Text] [Related]
8. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
9. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
Picker SM; Tauszig ME; Gathof BS
Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
[TBL] [Abstract][Full Text] [Related]
10. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
[TBL] [Abstract][Full Text] [Related]
11. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
[TBL] [Abstract][Full Text] [Related]
12. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
13. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.
Reikvam H; Marschner S; Apelseth TO; Goodrich R; Hervig T
Blood Transfus; 2010 Jul; 8(3):186-92. PubMed ID: 20671879
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology.
Salunkhe V; De Cuyper IM; Papadopoulos P; van der Meer PF; Daal BB; Villa-Fajardo M; de Korte D; van den Berg TK; Gutiérrez L
Platelets; 2019; 30(3):368-379. PubMed ID: 29553857
[TBL] [Abstract][Full Text] [Related]
16. Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice.
Caudrillier A; Mallavia B; Rouse L; Marschner S; Looney MR
PLoS One; 2015; 10(7):e0133022. PubMed ID: 26176623
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.
Moog R; Fröhlich A; Mayaudon V; Lin L
J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347
[TBL] [Abstract][Full Text] [Related]
18. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.
Ignatova AA; Karpova OV; Trakhtman PE; Rumiantsev SA; Panteleev MA
Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.
Sandgren P; Tolksdorf F; Struff WG; Gulliksson H
Vox Sang; 2011 Jul; 101(1):35-43. PubMed ID: 21175668
[TBL] [Abstract][Full Text] [Related]
20. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days.
Cookson P; Thomas S; Marschner S; Goodrich R; Cardigan R
Transfusion; 2012 May; 52(5):983-94. PubMed ID: 22014032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
